Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMPHNASDAQ:BGMNASDAQ:IVANASDAQ:NAGE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPHAmphastar Pharmaceuticals$23.18-1.7%$24.75$22.64▼$53.96$1.11B0.72494,740 shs221,782 shsBGMBGM Group$10.21+4.6%$12.52$5.26▼$17.17$948.89M1.2934,082 shs27,784 shsIVAInventiva$3.06+2.7%$3.37$1.53▼$4.05$285.07M0.7364,338 shs7,112 shsNAGENiagen Bioscience$12.71+1.0%$11.30$2.40▼$14.69$990.92M2.14998,227 shs727,210 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPHAmphastar Pharmaceuticals-1.72%-0.02%-10.90%-12.91%-39.90%BGMBGM Group+4.61%-20.36%-24.54%-4.76%+1,020,999,900.00%IVAInventiva+2.68%-3.47%-15.47%-0.33%+3.03%NAGENiagen Bioscience+1.03%-8.03%+7.89%+111.31%+365.57%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMPHAmphastar Pharmaceuticals4.3598 of 5 stars3.12.00.03.71.74.21.3BGMBGM GroupN/AN/AN/AN/AN/AN/AN/AN/AIVAInventiva2.7926 of 5 stars3.45.00.00.00.61.70.6NAGENiagen Bioscience1.5138 of 5 stars3.50.00.00.02.40.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMPHAmphastar Pharmaceuticals 2.25Hold$32.3339.52% UpsideBGMBGM Group 0.00N/AN/AN/AIVAInventiva 2.80Moderate Buy$10.40239.87% UpsideNAGENiagen Bioscience 3.00Buy$19.5053.42% UpsideCurrent Analyst Ratings BreakdownLatest IVA, BGM, NAGE, and AMPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/10/2025NAGENiagen BioscienceCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$13.00 ➝ $16.006/6/2025NAGENiagen BioscienceRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $23.005/27/2025NAGENiagen BioscienceCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$13.005/12/2025AMPHAmphastar PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral$45.00 ➝ $30.005/8/2025AMPHAmphastar PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$40.00 ➝ $35.004/10/2025AMPHAmphastar PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold4/4/2025IVAInventivaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $9.00(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMPHAmphastar Pharmaceuticals$731.97M1.49$4.92 per share4.71$15.23 per share1.52BGMBGM Group$25.10M39.55N/AN/A$7.34 per share1.39IVAInventiva$9.95M29.42N/AN/A($1.21) per share-2.53NAGENiagen Bioscience$99.60M10.05$0.06 per share212.68$0.60 per share21.18Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMPHAmphastar Pharmaceuticals$159.52M$2.768.407.046.1419.38%22.20%10.40%8/6/2025 (Estimated)BGMBGM Group-$1.44MN/A0.00∞N/AN/AN/AN/AN/AIVAInventiva-$199.34MN/A0.00N/AN/AN/AN/AN/AN/ANAGENiagen Bioscience$8.55M$0.1774.76∞N/A13.07%19.06%12.20%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMPHAmphastar PharmaceuticalsN/AN/AN/AN/AN/ABGMBGM GroupN/AN/AN/AN/AN/AIVAInventivaN/AN/AN/AN/AN/ANAGENiagen BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMPHAmphastar Pharmaceuticals0.802.952.02BGMBGM GroupN/AN/AN/AIVAInventivaN/A0.920.92NAGENiagen BioscienceN/A3.663.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMPHAmphastar Pharmaceuticals65.09%BGMBGM GroupN/AIVAInventiva19.06%NAGENiagen Bioscience15.41%Insider OwnershipCompanyInsider OwnershipAMPHAmphastar Pharmaceuticals27.50%BGMBGM Group58.66%IVAInventiva32.00%NAGENiagen Bioscience9.39%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMPHAmphastar Pharmaceuticals2,02847.14 million34.18 millionOptionableBGMBGM Group29897.22 million40.19 millionN/AIVAInventiva10095.66 million65.05 millionNot OptionableNAGENiagen Bioscience12078.77 million71.37 millionN/AIVA, BGM, NAGE, and AMPH HeadlinesRecent News About These CompaniesNAGE - Niagen Bioscience Inc Executives - MorningstarJuly 1 at 10:11 PM | morningstar.comMNiagen Bioscience (NASDAQ:NAGE) Stock Price Down 9.5% - Here's What HappenedJuly 1 at 4:36 PM | marketbeat.comEarnings Forecast & History for Niagen Bioscience Inc (NAGE) | Price ReactionsJuly 1 at 5:30 AM | investing.comNiagen Bioscience (NASDAQ:NAGE) Reaches New 1-Year High - What's Next?June 30, 2025 | marketbeat.com2NAGE : Breaking Update: Wendy Tak Wing YU Engages In Options Exercise At Niagen...June 27, 2025 | benzinga.com1NAGE : Engaging In Insider Activity, Kristin Patrick At Niagen Bioscience Exercises...June 27, 2025 | benzinga.comMajor Update: Frank Jaksch Jr At Niagen Bioscience Exercises Options, Realizing $0June 26, 2025 | benzinga.comOptions Exercise Update At Niagen Bioscience: Ann Cohen Engages, Resulting In $0June 26, 2025 | benzinga.comSteven Rubin At Niagen Bioscience Exercises Options Worth $0June 26, 2025 | benzinga.comNiagen Bioscience, Inc. (NAGE) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comNiagen Biosciences: Anti-Aging Market Leader And Prime Beneficiary Of Long-Term Demographic TrendsJune 24, 2025 | seekingalpha.comEven though Niagen Bioscience (NASDAQ:NAGE) has lost US$55m market cap in last 7 days, shareholders are still up 623% over 3 yearsJune 23, 2025 | finance.yahoo.comNiagen Bioscience (NASDAQ:NAGE) Raised to Strong-Buy at Wall Street ZenJune 22, 2025 | marketbeat.comNiagen Bioscience, Inc: Niagen Bioscience to Participate at the Roth 15th Annual London ConferenceJune 20, 2025 | finanznachrichten.deNiagen Bioscience to Participate at the Roth 15th Annual London ConferenceJune 20, 2025 | businesswire.comNiagen Bioscience (NASDAQ:NAGE) Shares Down 2.4% - Should You Sell?June 18, 2025 | marketbeat.comNiagen Bioscience (NASDAQ:NAGE) Downgraded to Buy Rating by Wall Street ZenJune 14, 2025 | marketbeat.comChromaDex Corp (OCD1.DU)June 11, 2025 | nz.finance.yahoo.comNiagen Bioscience to Participate in the BIO 2025 International ConventionJune 11, 2025 | businesswire.comNiagen Bioscience: High Conviction, High ExpectationsJune 11, 2025 | seekingalpha.comCanaccord Genuity Group Forecasts Strong Price Appreciation for Niagen Bioscience (NASDAQ:NAGE) StockJune 10, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonASML Keeps Buying Back Its Own Stock—Chasing Discount and UpsideBy Gabriel Osorio-Mazilli | June 25, 2025View ASML Keeps Buying Back Its Own Stock—Chasing Discount and UpsideWhy SailPoint May Cruise Past Cybersecurity Rivals in 2025By Nathan Reiff | June 18, 2025View Why SailPoint May Cruise Past Cybersecurity Rivals in 2025Lululemon Slips as Rivals Rally: 3 Stocks to WatchBy Dan Schmidt | June 30, 2025View Lululemon Slips as Rivals Rally: 3 Stocks to WatchAnalysts Are All In on This Tech Stock—Why You Should Be, TooBy Nathan Reiff | July 1, 2025View Analysts Are All In on This Tech Stock—Why You Should Be, TooIVA, BGM, NAGE, and AMPH Company DescriptionsAmphastar Pharmaceuticals NASDAQ:AMPH$23.18 -0.41 (-1.72%) Closing price 07/3/2025 03:50 PM EasternExtended Trading$23.18 0.00 (0.00%) As of 07/3/2025 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.BGM Group NASDAQ:BGM$10.21 +0.45 (+4.61%) As of 07/3/2025 03:05 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.Inventiva NASDAQ:IVA$3.06 +0.08 (+2.68%) As of 07/3/2025 02:17 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.Niagen Bioscience NASDAQ:NAGE$12.71 +0.13 (+1.03%) As of 07/3/2025 01:00 PM EasternNiagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
